For research use only. Not for use in humans.

Pinatuzumab (Anti-Siglec-2 / CD22)

Synonyms: DCDT2980S Cat.No.A3059 Purity:99%

Pinatuzumab (Anti-Siglec-2 / CD22) a humanised IgG1 monoclonal antibody targeting CD22. It has potential antineoplastic activity and can be used in research of Non-Hodgkin Lymphoma. MW : 146.64 KD.

Quality Control

Batch: A305901 Purity: 99% Protein concentration: 7.001mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Pinatuzumab (Anti-Siglec-2 / CD22) a humanised IgG1 monoclonal antibody targeting CD22. It has potential antineoplastic activity and can be used in research of Non-Hodgkin Lymphoma. MW : 146.64 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/27601593/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1313706-14-7
Isotype	Human IgG1
Source	CHO
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.